IL2 and B-cell chronic lymphocytic leukemia: In contrast to JAK inhibition with ruxolitinib (Figures 3A, C), early IL10 transcription (Figure 5E) and TNFα, released spontaneously from cultured CLL cells and increased by IL-2 and resiquimod, were both decreased significantly by ibrutinib (Figure 5D, right panel).